Real-World ravulizumab data: hope for PNH patients in poland
NCT ID NCT06633536
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 64 Polish adults with paroxysmal nocturnal hemoglobinuria (PNH) who are taking ravulizumab as part of their routine care. Researchers will track blood markers like LDH and how many patients need blood transfusions over time. The goal is to see if the drug works as well in everyday life as it did in clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ravulizumab
- What this could lead to
- If successful, this study could confirm that ravulizumab works well in everyday practice for managing PNH, supporting its continued use.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It only includes 64 patients in Poland, so findings may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
64 people
The number who actually took part.
- Started
-
Feb 2025
- Expected to finish
-
Aug 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult (aged ≥18) patients with PNH
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Adult (aged ≥18) patients with PNH receiving ravulizumab treatment in the frames of NDP in Poland. 2. Patients willing to participate in the study and signed ICF. Exclusion Criteria: 1. Those who participated in ravulizumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first ravulizumab infusion through NDP. 2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Paroxysmal nocturnal haemoglobinuria are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Bialystok, Poland
-
Research Site
Brzozów, Poland
-
Research Site
Bydgoszcz, Poland
-
Research Site
Gdansk, Poland
-
Research Site
Krakow, Poland
-
Research Site
Lodz, Poland
-
Research Site
Lublin, Poland
-
Research Site
Opole, Poland
-
Research Site
Szczecin, Poland
-
Research Site
Warsaw, Poland
-
Research Site
Wałbrzych, Poland